In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: Correlation with physico-chemical properties and oral activity

Pharmaceutical Research

Volumn 16, Issue 3, 1999, Pages 434-440

  Lowther, Nicholas ^a   Fox, Roy ^a   Faller, Bernard ^b   Nick, Hanspeter ^b   Jin, Yi ^b   Sergejew, Thomas ^b   Hirschberg, Yulia ^b   Oberle, Rebecca ^b,c   Donnelly, Harry ^d  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c R W JOHNSON PHARMACEUTICAL RES I   (United States)

^d Globepharm Ltd   (United Kingdom)

Author keywords

In vitro permeability; Intestinal drug transport; Iron chelator; Lipophilicity; Oral absorption; Solubility

Indexed keywords

3 HYDROXY 1 (2 HYDROXYETHYL) 2 HYDROXYPHENYLMETHYL 1H PYRIDIN 4 ONE; DEFERIPRONE; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIPOPHILICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032905413     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018886005136     Document Type: Article

References (32)

1. 1. H. P. Schnebli, I. Hassan, K. O. Hamilton, S. Lynch, Y. Jin, H. P. Nick, H. H. Peter, U. Junker-Walker, R. Ziel, S. C. Khanna, R. Dean, and R. J. Bergeron. Towards better chelation therapy: current concepts and research strategy, in The Development of Iron Chelators for Clinical Use, R. J. Bergeron and G. M. Brittenham (eds.), 1994, p. 131.
2. 2. J. B. Porter. A risk-benefit of iron-chelation therapy. Drug Saf. 17:407-421 (1997).
3. 3. R. C. Hider, G. J. Kontogiorghes, J. Silver, and M. A. Stockham. UK Patent GB-2117766 (1982).
4. 4. R. C. Hider, G. J. Kontogiorghes, and J. Silver. UK Patent GB-2118176 (1983).
5. 5. E. R. Huehns, J. B. Porter, and R. C. Hider. Selection of Hydroxypyridin-4-ones for the treatment of Iron Overload using in vitro and in vivo models. Haemoglobin 12:593-600 (1988).
6. 6. M. Gyparaki, J. B. Porter, S. Hirani, M. Streater, R. C. Hider, and E. R. Huehns. In vivo evaluation of Hydroxypyridone Iron Chelators in a Mouse Model. Acta Haematol (Basel) 78:217-221 (1987).
7. 7. G. J. Kontoghiorghes, L. Sheppard, A. V. Hoffbrand, J. Charalamous, J. Tiperpae, and M. J. Pippard. Iron Chelation Studies using Desferrioxamine and the Potential Oral Iron Chelator, 1,2,-Dimethyl-3-hydroxypyrid-4-one, in Normal and Iron Overloaded Rats. J. Clin. Pathol. 40:404-408 (1987).
8. 8. J. B. Porter, K. P. Hoyes, R. D. Abeysinghe, P. N. Brooks, E. R. Huehns, and R. C. Hider. Comparison of the Subacute Toxicity and Efficacy of 3-Hydroxypyridin-4-one Iron Chelators in Overloaded and Nonoverloaded Mice. Blood 78:2727-2734 (1991).
9. 9. G. J. Kontoghiorghes, M. A. Aldouri, L. Sheppard, and A. V. Hoffbrand. 1,2-Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for Treatment of Iron Overload. Lancet 1294 (1987).
10. 10. N. F. Olivieri, G. Koren, C. Hermann, D. Chung, R. McClelland, M. Freedman, P. St. Louis, and D. Templeton. Effective Iron Chelation with L1 in Patients with Thalassaemia Major. Iron Balance and Dose Response Studies. Blood 74:51a (1989).
11. 11. F. N. Al-Refaie, C. Hershko, A. V. Hoffbrand, M. Kosaryan, N. F. Olivieri, P. Tondury, and B. Wonke. Results of Long-Term Deferiprone (L1) Therapy: A Report by the International Study Group on Oral Iron Chelators. Br. J. Haematol. 91:224-229 (1995).
12. 12. V. Berdoukas, P. Bentley, H. Frost, and H. P. Schnebli. Toxicity of the oral iron chelator L1. Lancet. 341:1088 (1993).
13. 13. R. J. Motekaitis and A. E. Martell. Stabilities of the Iron(III) Chelates of 1,2-Dimethyl-3-hydroxy-4-pyridinone and Related Ligands. Inorg. Chim. Acta. 183:71-80 (1991).
14. 14. P. Artusson and J. Karlsson. Correlation between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells. Biochem. Biophys. Res. Commun. 175:880-885 (1991).
15. 15. G. L. Amidon, P. J. Sinko, and D. Fleisher. Estimating Human Fraction Absorbed: a Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-mediated compounds. Pharm. Res. 5:651-654 (1988).
16. 16. G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in vitro Drug Product Dissolution and in vivo Bioavailability. Pharm. Res. 12:413-420 (1995).
17. 17. P. L. Nicklin, W. J. Irwin, I. F. Hassan, and M. Mackay. Proline Uptake by Monolayers of Human Intestinal Absorptive (Caco-2) Cells in vitro. Biochim. Biophys. Acta. 1104:283-292 (1992).
18. 18. J. I. Wells in Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substances, Ellis Horwood, Wiley, Chichester, 1988, pp. 81-82.
19. 19. F. H. Clarke and N. M. Cahoon. Ionisation Constants by Curve Fitting: Determination of Partition and Distribution Coefficients of Acids and Bases and their Ions. J. Pharm. Sci. 76:611-620 (1987).
20. 20. A. Avdeef. pH-Metric logP. 2. Refinement of Partition Coefficients and Ionisation Constants of Multiprotic Substances. J. Pharm. Sci. 82:183-190 (1993).
21. 21. A. Avdeef. pH-Metric logP. 1. Difference Plots for Determining Ion-Pair Octanol-Water Partition Coefficients of Multiprotic Substances. Quant. Struct.-Act. Relat. 11:510-517 (1992).
22. 22. R. J. Bergeron, J. Wiegand, J. B. Dionis, M. Egli-Karmakka, J. Frei, A. Huxley-Tencer, and H. H. Peter. Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators. J. Med. Chem. 34:2072-2078 (1991).
23. 23. G. F. Smith, W. H. McCurdy, and H. Diehl. Analyst 77:418-422 (1952).
24. 24. R. J. Bergeron, R. R. Streiff, J. Wiegand, J. R. T. Vinson, G. Luchetta, K. M. Evans, H. H. Peter, and H. B. Jenny. A Comparative Evaluation of Iron Clearance Models. Ann. NY Acad. Sci. 612:378-393 (1990).
25. 25. R. L. Elliott, G. L. Amidon, and E. N. Lightfoot. A Convective Mass Transfer Model for Determining Intestinal Wall Permeabilities: laminar Flow in a Circular Tube. J. Theor. Biol. 87:757-771 (1980).
26. 26. R. C. Reid, J. M. Prausnitz, and T. K. Sherwood, in The Properties of Liquids and Gases, McGraw-Hill, New York, 1977, pp. 57-59.
27. 27. S. Yee and G. L. Amidon. Intestinal Absorption Mechanism of Three Angiolensin-Converting Enzyme Inhibitors: Quinapril, Benazepril and CGS 16617. Pharm. Res. 7:S155 (1990).
28. 28. T. W. von Geldern, D. J. Hoffman, J. A. Kester, H. N. Nellans, B. D. Dayton, S. V. Calzadilla, K. C. Marsh, L. Hernandez, W. Chiou, D. B. Dixon, J. R. Wu-Wong, and T. J. Opgenorth. Azole Endothelin Antagonists. 3. Using A logP as a Tool to Improve Absorption. J. Med. Chem. 39:982-991 (1996).
29. 29. S. A. Kaplan. Biopharmaceutical Considerations in Drug Formulation Design and Evaluation. Drug Metab. Rev. 1:15-33 (1972).
30. 30. J. C. Shah, J. R. Chen, and D. Chow. Preformulation Study of Etoposide: Identification of Physicochemical Characteristics Responsible for the Low and Erratic Oral Bioavailability of Etoposide. Pharm. Res. 6:408-412 (1989).
31. 31. C. A. Finch and H. Hubers. Perspectives in Iron Metabolism. New Engl. J. Med. 306:1520 (1982).
32. 32. C. A. Finch, H. A. Ragan, I. A. Dyer, and J. D. Cook. Body Iron Loss in Animals. Proc. Soc. Exp. Biol. Med. 159:335-338 (1978).